BioSpace News Archive

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a collaboration with CONNECT, an international collaborative network of pediatric cancer centers, to conduct a Phase 2 clinical trial to evaluate REZLIDHIA.

Elevance Health announced that it has entered into an agreement to acquire Paragon Healthcare, Inc., a company specializing in life-saving and life-giving infusible and injectable therapies.

OcuTerra Therapeutics, Inc. today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place on January 8-11, 2024 in San Francisco.

Apertura Gene Therapy today unveiled its proprietary engineered Adeno-Associated Virus (AAV) capsids that bind to the human Transferrin Receptor 1 (TfR1).

Viridian Therapeutics, Inc. today announced that its President and Chief Executive Officer, Steve Mahoney, will present an overview of the company along with its upcoming corporate priorities at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 7:30am PT / 10:30am ET in San Francisco.

MMI (Medical Microinstruments, Inc.) today announced the company has been invited to participate in the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco.

Lyndra Therapeutics today announced positive data from the STARLYNG-1 (LYN-005-C-301) study, comparing the pharmacokinetic (PK) profile of oral weekly risperidone (LYN-005) with immediate-release Risperdal administered daily to adults living with schizophrenia and schizoaffective disorder.

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 8:30 a.m. PT in San Francisco, CA.

Scholar Rock, a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, provided recent corporate updates and highlighted upcoming priorities for 2024.

Sagard Healthcare announced several developments and milestones for the strategy, including the closing of a $250 million permanent credit facility and the completion of nearly $250 million of new investments.